190 related articles for article (PubMed ID: 29692658)
21. Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia.
Galton DA
Leuk Lymphoma; 1992 Aug; 7(5-6):343-50. PubMed ID: 1493435
[TBL] [Abstract][Full Text] [Related]
22. How I treat atypical chronic myeloid leukemia.
Gotlib J
Blood; 2017 Feb; 129(7):838-845. PubMed ID: 27899359
[TBL] [Abstract][Full Text] [Related]
23. Hydroxyurea- a cost effective treatment in developing countries for Atypical Chronic Myeloid Leukemia (aCML): Case Report of Two Patients.
Hassan Z; Iqbal A; Zahoor S; Ali I; Iqbal MM; Bibi R
J Oncol Pharm Pract; 2022 Jun; 28(4):1014-1018. PubMed ID: 35018854
[TBL] [Abstract][Full Text] [Related]
24. Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia.
Fontana D; Ramazzotti D; Aroldi A; Redaelli S; Magistroni V; Pirola A; Niro A; Massimino L; Mastini C; Brambilla V; Bombelli S; Bungaro S; Morotti A; Rea D; Stagno F; Martino B; Campiotti L; Caocci G; Usala E; Merli M; Onida F; Bregni M; Elli EM; Fumagalli M; Ciceri F; Perego RA; Pagni F; Mologni L; Piazza R; Gambacorti-Passerini C
Hemasphere; 2020 Dec; 4(6):e497. PubMed ID: 33196013
[TBL] [Abstract][Full Text] [Related]
25. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
[TBL] [Abstract][Full Text] [Related]
26. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
27. Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm.
Fend F; Horn T; Koch I; Vela T; Orazi A
Leuk Res; 2008 Dec; 32(12):1931-5. PubMed ID: 18555525
[TBL] [Abstract][Full Text] [Related]
28. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
Srour SA; Devesa SS; Morton LM; Check DP; Curtis RE; Linet MS; Dores GM
Br J Haematol; 2016 Aug; 174(3):382-96. PubMed ID: 27061824
[TBL] [Abstract][Full Text] [Related]
29. Atypical CML with TET2 mutation, associated with NRAS and KRAS: A case report and literature review.
Abuzneid YS; Alzeerelhouseini HIA; Marzouqa N; Yaghi Y; Al-Ihribat AR; Alqam B; Krama A
Ann Med Surg (Lond); 2021 Nov; 71():102980. PubMed ID: 34840744
[TBL] [Abstract][Full Text] [Related]
30. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
31. Granulocytic sarcoma in a patient with chronic myeloid leukaemia in complete haematological, cytogenetic and molecular remission.
Kittai A; Yu EM; Tabbara I
BMJ Case Rep; 2014 Dec; 2014():. PubMed ID: 25538217
[TBL] [Abstract][Full Text] [Related]
32. Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia.
Kröger N; Eikema DJ; Köster L; Beelen D; de Wreede LC; Finke J; Koenecke C; Niederwieser D; Bornhäuser M; Schoenland S; Potter V; Wolschke C; Maertens J; Theobald M; Kobbe G; Itälä-Remes M; Wulf G; Kahls P; Forcade E; Greinix H; Masszi T; Yakoub-Agha I; Chalandon Y; Robin M;
Br J Haematol; 2019 May; 185(4):725-732. PubMed ID: 30820933
[TBL] [Abstract][Full Text] [Related]
33. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
34. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group.
Bennett JM; Catovsky D; Daniel MT; Flandrin G; Galton DA; Gralnick H; Sultan C; Cox C
Br J Haematol; 1994 Aug; 87(4):746-54. PubMed ID: 7986717
[TBL] [Abstract][Full Text] [Related]
35.
Linder K; Iragavarapu C; Liu D
Biomark Res; 2017; 5():33. PubMed ID: 29225884
[TBL] [Abstract][Full Text] [Related]
36. Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases.
Jiang H; Wu Z; Ren LI; Tao D; Tong H
Oncol Lett; 2016 Jan; 11(1):689-692. PubMed ID: 26870268
[TBL] [Abstract][Full Text] [Related]
37. Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine.
Liu L; Song X; Dong W; Li Z; Guo D
Front Oncol; 2024; 14():1353818. PubMed ID: 38384813
[TBL] [Abstract][Full Text] [Related]
38. Atypical Chronic Myelogenous Leukemia,
Diamantopoulos PT; Viniou NA
Front Oncol; 2021; 11():722507. PubMed ID: 34868917
[TBL] [Abstract][Full Text] [Related]
39. Expression of myelopoiesis-associated microRNA in bone marrow cells of atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia.
Hussein K; Büsche G; Muth M; Göhring G; Kreipe H; Bock O
Ann Hematol; 2011 Mar; 90(3):307-13. PubMed ID: 20842500
[TBL] [Abstract][Full Text] [Related]
40. Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice.
Tefferi A; Elliott M; Pardanani A
Curr Opin Hematol; 2015 Mar; 22(2):171-6. PubMed ID: 25575036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
